Ovarian Cancer 3

1. Front Matter

   Pages i-xix

   PDF

2. Genetics of Ovarian Cancer

   1. Front Matter

      Pages 1-1

      PDF

   2. The genetic epidemiology of ovarian cancer

      • D. F. Easton, D. Ford, F. E. Matthews, J. Peto

      Pages 3-12

   3. Genetic epidemiology of familial ovarian cancer in Utah

      • D. E. Goldgar, K. Rowe, C. M. Lewis, M. McDonald, K. Gholami, L. Cannon-Albright et al.

      Pages 13-21

   4. Isolating tumour suppressor genes relevant to ovarian carcinoma — the role of loss of heterozygosity

      • W. D. Foulkes, J. Trowsdale

      Pages 23-38

   5. The BRCA1 gene in sporadic breast and ovarian cancer

      • D. M. Black, E. Solomon

      Pages 39-44

   6. Allele losses on chromosome 17 in ovarian tumours

      • C. M. Steel, D. M. Eccles, L. Gruber, M. Wallace, A. Lessels, J. M. Morsman et al.

      Pages 45-52

   7. Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens

      • I. G. Campbell, W. D. Foulkes, T. A. Jones, L. G. Poels, J. Trowsdale

      Pages 53-59

   8. New insights into the genetics of human ovarian epithelial tumor development

      • S. Zweizig, J. Zheng, M. Wan, T. M. Kim, M. Velicescu, J. Gosewehr et al.

      Pages 61-73

3. Tumour Biology

   1. Front Matter

      Pages 75-75

      PDF

   2. Molecular and biological factors in the pathogenesis of ovarian cancer

      • J. S. Berek, O. Martínez-Maza

      Pages 77-87

   3. Cytokines and ovarian cancer

      • M. S. Naylor, F. Burke, F. R. Balkwill

      Pages 89-97

   4. Growth factors and receptors in ovarian cancer

      • R. Leake, A. Barber, O. Owens, S. Langdon, B. Miller

      Pages 99-108

   5. Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-α

      • R. C. Bast Jr, J. Wiener, S. Kassim, S. Wu, C. M. Boyer, K. De Sombre et al.

      Pages 109-113

   6. TNF, LT and IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer

      • G. Granger, T. Gatanaga, R. Burger, E. Grosen, M. Berman, R. DiSaia

      Pages 115-119

   7. Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid

      • Y. Xu, G. B. Mills

      Pages 121-135

4. Early Ovarian Cancer and Borderline Tumours

   1. Front Matter

      Pages 137-137

      PDF

   2. Update on early ovarian cancer and cancer developing in benign ovarian tumors

      • R. E. Scully, D. A. Bell, G. M. Abu-Jawdeh

      Pages 139-144

   3. Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer

      • H. Salazar, A. K. Godwin, L. A. Getts, J. R. Testa, M. Daly, N. Rosenblum et al.

      Pages 145-156

   4. Human ovarian surface epithelium: growth patterns and differentiation

      • N. Auersperg, S. L. Maines-Bandiera, P. A. Kruk

      Pages 157-169

The Helene Harris Memorial Trust has become recognized as providing one of the most important international fora for the presentation of research in ovarian cancer. Four biennial meetings have taken place, the most recent of which was held between May 11-14, 1993, in Toronto, Canada. This forum has grown in stature from its inception in 1987 and has brought together interdisciplinary clinical and scientific researchers from around the world who are endeavouring to perform 'cutting edge' studies in the field. The assembled group of presti­ gious investigators met on this occasion to present their data, to exchange ideas, and to arrange collaborations with the goal of developing new means of detection, treatment and cure of ovarian cancer. The incentive for the establishment of the Trust and its international forum was the prema­ ture loss through ovarian cancer of Helene Harris, the wife of Mr John Harris. Mr Harris and the Trustees looked for a meaningful way to honour the memory of Helene and to advance the noble cause of gaining an increase in the scientific knowledge of the subject. For those of us who spend most of our waking hours assisting patients and their families who are devastated by this disease, the Trust's generosity provides inspiration, hope and the opportunity for their practical application in a unique professional forum.

• BRCA
• TNF
• cancer
• cancer treatment
• carcinoma
• cell
• cytokines
• epidemiology
• genetics
• immunotherapy
• interferon
• lymphocytes
• ovarian cancer
• therapy
• tumor

• Department of Obstetrics and Gynaecology, Northern General Hospital, Sheffield University, Sheffield, UK

  Frank Sharp, Tony Blackett

• The Samaritan Hospital for Women, St Mary’s Hospital Medical School, London, UK

  Peter Mason

• Division of Gynecologic Oncology, UCLA School of Medicine, Los Angeles, USA

  Jonathan Berek

Policies and ethics